Baker Ellis Asset Management LLC purchased a new position in Albemarle Co. (NYSE:ALB) during the fourth quarter, HoldingsChannel.com reports. The firm purchased 19,790 shares of the specialty chemicals company’s stock, valued at approximately $2,531,000.

A number of other institutional investors have also added to or reduced their stakes in the business. Scotia Capital Inc. grew its position in Albemarle by 0.5% in the second quarter. Scotia Capital Inc. now owns 2,022 shares of the specialty chemicals company’s stock valued at $213,000 after acquiring an additional 10 shares during the last quarter. L & S Advisors Inc grew its position in Albemarle by 2.2% in the second quarter. L & S Advisors Inc now owns 4,200 shares of the specialty chemicals company’s stock valued at $443,000 after acquiring an additional 90 shares during the last quarter. Thrivent Financial For Lutherans grew its position in Albemarle by 2.2% in the second quarter. Thrivent Financial For Lutherans now owns 4,240 shares of the specialty chemicals company’s stock valued at $447,000 after acquiring an additional 90 shares during the last quarter. Zacks Investment Management grew its position in Albemarle by 2.4% in the second quarter. Zacks Investment Management now owns 4,767 shares of the specialty chemicals company’s stock valued at $503,000 after acquiring an additional 111 shares during the last quarter. Finally, Golden Gate Private Equity Inc. grew its position in Albemarle by 1.5% in the third quarter. Golden Gate Private Equity Inc. now owns 25,870 shares of the specialty chemicals company’s stock valued at $3,526,000 after acquiring an additional 370 shares during the last quarter. Hedge funds and other institutional investors own 88.03% of the company’s stock.

Albemarle Co. (ALB) traded down $0.31 during trading on Tuesday, hitting $111.37. The company had a trading volume of 2,098,674 shares, compared to its average volume of 2,273,062. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.56 and a current ratio of 2.11. The firm has a market capitalization of $12,641.80, a price-to-earnings ratio of 14.48, a P/E/G ratio of 1.50 and a beta of 1.69. Albemarle Co. has a one year low of $90.35 and a one year high of $144.99.

Albemarle (NYSE:ALB) last posted its quarterly earnings data on Wednesday, November 8th. The specialty chemicals company reported $1.08 EPS for the quarter, topping the Zacks’ consensus estimate of $1.07 by $0.01. The company had revenue of $755.00 million for the quarter, compared to analyst estimates of $732.19 million. Albemarle had a return on equity of 11.61% and a net margin of 30.07%. The firm’s quarterly revenue was up 15.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.91 earnings per share. analysts predict that Albemarle Co. will post 4.46 EPS for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, January 2nd. Investors of record on Friday, December 15th were paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 1.15%. The ex-dividend date was Thursday, December 14th. Albemarle’s dividend payout ratio is currently 16.56%.

ALB has been the topic of a number of recent analyst reports. Jefferies Group reiterated a “buy” rating on shares of Albemarle in a research report on Tuesday, October 24th. Royal Bank of Canada reiterated a “buy” rating and issued a $149.00 target price on shares of Albemarle in a research report on Wednesday, October 18th. Zacks Investment Research upgraded Albemarle from a “hold” rating to a “buy” rating and set a $157.00 target price on the stock in a research report on Tuesday, October 17th. KeyCorp lifted their target price on Albemarle from $125.00 to $150.00 and gave the company a “buy” rating in a research report on Monday, October 16th. Finally, Instinet restated a “buy” rating and set a $154.00 price target (up from $146.00) on shares of Albemarle in a report on Friday, October 13th. Nine research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $127.78.

COPYRIGHT VIOLATION WARNING: “Baker Ellis Asset Management LLC Takes Position in Albemarle Co. (ALB)” was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://theolympiareport.com/2018/01/30/baker-ellis-asset-management-llc-takes-position-in-albemarle-co-alb.html.

About Albemarle

Albemarle Corporation is a global developer, manufacturer and marketer of highly-engineered specialty chemicals. The Company operates through three segments: Lithium and Advanced Materials, Bromine Specialties and Refining Solutions. Lithium and Advanced Materials segment consist of two product categories: Lithium and Performance Catalyst Solutions.

Want to see what other hedge funds are holding ALB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Albemarle Co. (NYSE:ALB).

Institutional Ownership by Quarter for Albemarle (NYSE:ALB)

Receive News & Ratings for Albemarle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle and related companies with MarketBeat.com's FREE daily email newsletter.